Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Total Liabilities (2016 - 2026)

Champions Oncology has reported Total Liabilities over the past 16 years, most recently at $24.1 million for Q1 2026.

  • For Q1 2026, Total Liabilities fell 4.33% year-over-year to $24.1 million; the TTM value through Jan 2026 reached $24.1 million, down 4.33%, while the annual FY2025 figure was $28.6 million, 1.92% up from the prior year.
  • Total Liabilities for Q1 2026 was $24.1 million at Champions Oncology, down from $25.9 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $29.7 million in Q2 2023 and troughed at $24.1 million in Q1 2026.
  • A 5-year average of $26.8 million and a median of $27.0 million in 2025 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: surged 41.77% in 2022 and later fell 12.91% in 2024.
  • Year by year, Total Liabilities stood at $27.2 million in 2022, then increased by 3.71% to $28.2 million in 2023, then decreased by 12.91% to $24.6 million in 2024, then increased by 5.59% to $25.9 million in 2025, then dropped by 7.18% to $24.1 million in 2026.
  • Business Quant data shows Total Liabilities for CSBR at $24.1 million in Q1 2026, $25.9 million in Q4 2025, and $27.0 million in Q3 2025.